Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

ABSTRACT:

SUBMITTER: Davies A 

PROVIDER: S-EPMC6494978 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature